This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
by Zacks Equity Research
Gilead Sciences and Nuvalent are in the spotlight following positive updates on key candidates.
Why Novavax is Gaining Ground in COVID-19 Vaccine Race
by Andrew Rocco
Though Novavax is behind in the COVID-19 vaccine race, a blockbuster deal with Sanofi and a differentiated product means the stock offers the best reward prospects in the industry.
Moderna (MRNA) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $69.17, representing a +1.3% change from its previous close.
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
by Zacks Equity Research
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
Company News for Sep 13, 2024
by Zacks Equity Research
Companies in The News Are: KR,SIG,ALK,MRNA
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
by Kinjel Shah
VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab
by Zacks Equity Research
The Committee for Medicinal Products for Human Use recommends marketing authorization for Moderna's updated mRNA COVID-19 jab, Spikevax.
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
by Zacks Equity Research
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
by Zacks Equity Research
The European Commission approves GSK's RSV vaccine, Arexvy, for use in adults aged 50-59 years with increased risk of the disease.
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs
by Sundeep Ganoria
On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.
Merck (MRK) Falls 10% in 3 Months: Should You Buy the Dip?
by Kinjel Shah
Declining estimates and the recent price drop make investors skeptical about holding Merck's (MRK) stock.
Pharma Stock Roundup: FDA Nod to PFE, MRNA New COVID Jabs & More
by Kinjel Shah
LLY's phase III study shows that tirzepatide reduces the risk of developing type II diabetes. FDA approves PFE and MRNA's updated COVID-19 vaccine.
Pfizer (PFE), BioNTech COVID-Flu Combo Shot Study Falters
by Zacks Equity Research
Pfizer's (PFE) COVID and flu combination vaccine demonstrates a continued trend of higher responses against influenza A but fails to show non-inferiority against the influenza B strain.
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
by Zacks Equity Research
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
Pfizer (PFE) Touts RSV Jab Benefit in Immunocompromised Adults
by Zacks Equity Research
Results from a late-stage study show that Pfizer's (PFE) RSV vaccine generated strong neutralizing responses in immunocompromised adults after receiving a single dose.
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
by Zacks Equity Research
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip
by Kinjel Shah
Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.
Novavax (NVAX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
On Novavax's (NVAX) second-quarter earnings call, investors will likely focus on the company's pipeline updates and collaboration revenue numbers from its recently entered deal with Sanofi.
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Ekta Bagri
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
by Zacks Equity Research
Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Ahan Chakraborty
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
5 Biotech Stocks to Bet On Bright Industry Prospects
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.